Those on the GLP-1 dulaglutide were found to have a 14% risk reduction of cognitive decline compared with those on placebo
Groups at genuine risk of deficiency include vegans, older adults, people with pernicious anaemia, those on long-term metformin, and individuals who have had gastric surgery
Then select Pay With Debit Cards under Payment Methods
JAMA Cardiology 8(3):213221 Reddy YNV, Koepp KE, Carter R, Win S, Jain CC, Olson TP, Johnson BD, Rea R, Redfield MM, Borlaug BA (2023) Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: the RAPID-HF Randomized Clinical Trial
A schema with the study design is depicted in Supplementary Fig
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, such as type 2 diabetes or hypertension